SEE MORE Act

Bill: 116-s-2020
Sponsor: full_name: Sen. Casey, Robert P., Jr. [D-PA]
Introduced: 2019-06-27
Policy area: Health
Subjects: Congressional oversight

Digestive and metabolic diseases

Health facilities and institutions

Health technology, devices, supplies

Hearing, speech, and vision care

Medical tests and diagnostic methods

Medicare
Latest action: action_date: 2019-06-27
text: Read twice and referred to the Committee on Finance.

Summaries:
action_date: 2019-06-27
action_desc: Introduced in Senate
text: <p><b>Screenings for Eye Evaluation, Monitoring, Observation, Review, and Examination Act or the SEE MORE Act</b></p> <p>This bill exempts telehealth services involving remote imaging for chronic eye disease from specified requirements, such as geographic restrictions, under Medicare.</p>

tv_txt: II 116th CONGRESS 1st Session S. 2020 IN THE SENATE OF THE UNITED STATES June 27, 2019 Mr. Casey (for himself and Mr. Grassley ) introduced the following bill; which was read twice and referred to the Committee on Finance A BILL To amend title XVIII of the Social Security Act to expand the use of telehealth services for remote imaging for chronic eye disease.

1. Short title This Act may be cited as the Screenings for Eye Evaluation, Monitoring, Observation, Review, and Examination Act or the SEE MORE Act . 2. Expanding the use of telehealth services for remote imaging for chronic eye disease Section 1834(m) of the Social Security Act ( 42 U.S.C. 1395m(m) ) is amended— (1) in paragraph (4)(C)(i), by striking and (7) and inserting (7), and (8) ; and (2) by adding at the end the following new paragraph: (8) Treatment of remote imaging for chronic eye disease (A) Non-application of originating site requirements The requirements described in paragraph (4)(C) shall not apply with respect to telehealth services furnished on or after January 1, 2020, for purposes of providing remote imaging for chronic eye disease, as determined by the Secretary, including diabetic eye disease and glaucoma. Such screenings and services shall include the use of FDA-approved ocular imaging techniques and technologies, including artificial intelligence technologies, shown to support the accurate diagnosis or monitoring or treatment of diabetic retinopathy, glaucoma, or other chronic eye disease, as determined by the Secretary. (B) No originating site facility fee for new sites No facility fee shall be paid under paragraph (2)(B) to an originating site with respect to a telehealth service described in subparagraph (A) if the originating site does not otherwise meet the requirements for an originating site under paragraph (4)(C). (C) Report Not later than 5 years after the date of the enactment of this paragraph, the Secretary shall submit to Congress a report on the impact of this paragraph with respect to telehealth services on— (i) the utilization of health care items and services related to diabetes and glaucoma; (ii) health outcomes related to diabetes and glaucoma; and (iii) the rates of specialty referrals and the rate for completion of a specialty visit within 90 days of referral for individuals with diabetic retinopathy or glaucoma after receiving telehealth services. .